Tumor-specific mutant antigen-derived major histocompatibility complex class I or II complex

Tumor-specific mutant antigen-derived major histocompatibility complex (MHC) class I/II complexes are protein complexes formed when MHC class I or class II molecules present peptides arising from non-synonymous somatic mutations unique to tumor cells ("neoantigens") on the cell surface. These complexes are recognized by T cell receptors (TCRs) on CD8+ (MHC I) or CD4+ (MHC II) T cells, driving a tumor-specific immune response. Their formation and recognition form the molecular basis for cutting-edge cancer immunotherapies, such as neoantigen vaccines and adoptive T cell therapies. Unlike shared tumor antigens, these neoantigen-MHC complexes represent truly tumor-specific, mutation-derived signals that can be exploited for highly selective immune targeting, though their presentation is subject to immune editing and tumor evasion mechanisms.

Other names

Neoantigen-MHC complexTumor-specific neoantigen-MHC I/II complexMutant peptide-MHC complex

Drugs or therapies targeting these complexes work by promoting immune recognition of tumor cells via T cell activation, restoring immune surveillance, or boosting antitumor immunity through vaccine or cell therapy approaches